文献速递消化系统肿瘤

替莫唑胺序贯低剂量伊匹木单抗联合纳武利尤单抗治疗微卫星稳定、O6-甲基鸟嘌呤-DNA甲基转移酶沉默的转移性结直肠癌:MAYA试验

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.
PubMed 文献 · J Clin Oncol · 2022-03-08

MAYA是一项多中心单臂II期试验,评估替莫唑胺引导后低剂量伊匹木单抗联合纳武利尤单抗在微卫星稳定且MGMT沉默的转移性结直肠癌中的疗效与安全性。716例预筛患者中204例(29%)分子合格,135例开始替莫唑胺引导,33例(24%)疾病控制后进入联合治疗部分。中位随访23.1个月,8个月无进展生存率为36%,中位无进展生存期7.0个月,中位总生存期18.4个月,总缓解率45%。

要点

  • 替莫唑胺引导后低剂量伊匹木单抗联合纳武利尤单抗在MSS且MGMT沉默的转移性结直肠癌中显示持久临床获益。
  • 8个月无进展生存率36%,中位无进展生存期7.0个月,中位总生存期18.4个月,总缓解率45%。
  • 3-4级免疫相关不良事件包括皮疹(6%)、结肠炎(3%)和垂体炎(3%),未报告意外不良事件或治疗相关死亡。

核心结论

  • MAYA研究提供概念验证,替莫唑胺引导后低剂量伊匹木单抗联合纳武利尤单抗可能在MSS且MGMT沉默的转移性结直肠癌中诱导持久临床获益。

研究设计与样本

  • 多中心、单臂II期试验,评估替莫唑胺引导后低剂量伊匹木单抗联合纳武利尤单抗的免疫增敏策略。
  • 患者为经治的转移性结直肠癌,中心预筛MSS状态和MGMT沉默(免疫组化MGMT表达缺失加焦磷酸测序MGMT甲基化)。
  • 合格患者接受两个引导周期口服替莫唑胺150 mg/sqm每日一次,第1-5天,每4周一次(第一治疗部分),无进展后联合伊匹木单抗1 mg/kg每8周一次和纳武利尤单抗480 mg每4周一次(第二治疗部分)。
  • 主要终点为从入组起计算、开始第二治疗部分患者的8个月无进展生存率,决策规则为27例中至少4例在8个月时无进展。

主要发现

  • 716例预筛患者中204例(29%)分子合格,135例开始第一治疗部分。
  • 135例中102例(76%)因死亡或疾病进展在替莫唑胺引导期间停药,33例(24%)达到疾病控制并开始第二治疗部分,构成最终研究人群。
  • 中位随访23.1个月(四分位距14.9-24.6个月),8个月无进展生存率为36%。
  • 中位无进展生存期7.0个月,中位总生存期18.4个月,总缓解率45%。
  • 3-4级免疫相关不良事件为皮疹(6%)、结肠炎(3%)和垂体炎(3%),未报告意外不良事件或治疗相关死亡。

临床怎么用

  • 作者认为,替莫唑胺引导后低剂量伊匹木单抗联合纳武利尤单抗可能在MSS且MGMT沉默的转移性结直肠癌中诱导持久临床获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This is a multicenter, single-arm phase II trial evaluating the efficacy and safety of an immune-sensitizing strategy with temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab in patients with microsatellite-stable (MSS) and O6-methylguanine-DNA methyltransferase (MGMT)-silenced metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with pretreated mCRC were centrally prescreened for MSS status and MGMT silencing (ie, lack of MGMT expression by immunohistochemistry plus MGMT methylation by pyrosequencing). Eligible patients received two priming cycles of oral temozolomide 150 mg/sqm once daily, days 1-5, once every 4 weeks (first treatment part) followed, in absence of progression, by its combination with ipilimumab 1 mg/kg once every 8 weeks and nivolumab 480 mg once every 4 weeks (second treatment part). The primary end point was the 8-month progression-free survival (PFS) rate calculated from enrollment in patients who started the second treatment part, with ≥ 4 out of 27 subjects progression-free by the 8-month time point as decision rule. RESULTS: Among 716 prescreened patients, 204 (29%) were molecularly eligible and 135 started the first treatment part. Among these, 102 (76%) were discontinued because of death or disease progression on temozolomide priming, whereas 33 patients (24%) who achieved disease control started the second treatment part and represented the final study population. After a median follow-up of 23.1 months (interquartile range, 14.9-24.6 months), 8-month PFS rate was 36%. Median PFS and overall survival were 7.0 and 18.4 months, respectively, and overall response rate was 45%. Grade 3-4 immune-related adverse events were skin rash (6%), colitis (3%), and hypophysitis (3%). No unexpected adverse events or treatment-related deaths were reported. CONCLUSION: The MAYA study provided proof-of-concept that a sequence of temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab may induce durable clinical benefit in MSS and MGMT-silenced mCRC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Morano F, Raimondi A, Pagani F, et al. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. J Clin Oncol. 2022. PMID: 35258987. doi:10.1200/JCO.21.02583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。